HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., Jacobson, I., Tran, T. T., Nahass, R., Hinestrosa, F., Herring, R., Bennet, M., Yang, J. C., Stamm, L. M., An, D., Dvory-Sobol, H., Brainard, D. M., McHutchison, J. G., Schiff, E., Davis, M., Etzkorn, K., Chung, R. T., Pound, D., Rodriguez-Torres, M., Reddy, K. R., Younes, Z., Gane, E. J. ELSEVIER SCIENCE BV. 2016: S139–S140

View details for DOI 10.1016/S0168-8278(16)01645-7

View details for Web of Science ID 000398711700015